MX2021006326A - Inhibidores de pcna. - Google Patents
Inhibidores de pcna.Info
- Publication number
- MX2021006326A MX2021006326A MX2021006326A MX2021006326A MX2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A
- Authority
- MX
- Mexico
- Prior art keywords
- pcna
- inhibitors
- pcna inhibitors
- modulators
- compositions
- Prior art date
Links
- 101150008755 PCNA gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108050006400 Cyclin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220014P | 2015-09-17 | 2015-09-17 | |
| US201662313592P | 2016-03-25 | 2016-03-25 | |
| US201662340964P | 2016-05-24 | 2016-05-24 | |
| PCT/US2016/052310 WO2017049206A1 (en) | 2015-09-17 | 2016-09-16 | Pcna inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006326A true MX2021006326A (es) | 2022-12-16 |
Family
ID=58289682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006326A MX2021006326A (es) | 2015-09-17 | 2016-09-16 | Inhibidores de pcna. |
| MX2018003301A MX382996B (es) | 2015-09-17 | 2016-09-16 | Inhibidores de pcna |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003301A MX382996B (es) | 2015-09-17 | 2016-09-16 | Inhibidores de pcna |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10550070B2 (enExample) |
| EP (2) | EP3349754B9 (enExample) |
| JP (4) | JP6966996B2 (enExample) |
| KR (2) | KR102768838B1 (enExample) |
| CN (2) | CN108348512B (enExample) |
| AU (3) | AU2016324158B2 (enExample) |
| CA (1) | CA2999080C (enExample) |
| ES (1) | ES3040726T3 (enExample) |
| IL (4) | IL282400B (enExample) |
| MX (2) | MX2021006326A (enExample) |
| WO (1) | WO2017049206A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10420840B2 (en) * | 2015-04-10 | 2019-09-24 | Rll, Llc | Anticancer therapeutic agents |
| KR102768838B1 (ko) | 2015-09-17 | 2025-02-14 | 시티 오브 호프 | Pcna 억제제 |
| WO2019133501A1 (en) * | 2017-12-29 | 2019-07-04 | Groupon, Inc. | Methods and systems for generating a supply index indicative of a quality of available supply |
| US11551247B1 (en) | 2017-12-29 | 2023-01-10 | Groupon, Inc. | Methods and systems for determining a travel propensity configured for use in the generation of a supply index indicative of a quality of available supply |
| CN117460714A (zh) * | 2021-04-30 | 2024-01-26 | 希望之城 | 用于癌症治疗的pcna抑制剂和egfr抑制剂 |
| CA3245082A1 (en) * | 2022-03-07 | 2023-09-14 | City Of Hope | PCNA INHIBITORS AND RELATED USES |
| WO2025054318A1 (en) * | 2023-09-06 | 2025-03-13 | City Of Hope | Pcna inhibitors and uses thereof |
| CN117603081A (zh) * | 2023-11-28 | 2024-02-27 | 沈阳药科大学 | N-(2-((2-(3-甲氧基苯氧基)苯基)氨基)-2-乙酰氧基)-1-萘胺的制备方法 |
| CN120097860A (zh) | 2023-12-05 | 2025-06-06 | 杜心赟 | 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途 |
| WO2025184571A1 (en) * | 2024-03-01 | 2025-09-04 | City Of Hope | Pcna inhibitors for the treatment of myc family associated cancers |
| CN118546074B (zh) * | 2024-05-27 | 2025-06-06 | 安徽贝克制药股份有限公司 | 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用 |
| CN118459363B (zh) * | 2024-05-27 | 2024-12-17 | 安徽贝克制药股份有限公司 | 一种氟取代增殖细胞核抗原抑制剂及其制备方法和其应用 |
| WO2026085107A1 (en) * | 2024-10-15 | 2026-04-23 | City Of Hope | Formulation of a pcna inhibitor |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1295611A (en) * | 1916-07-29 | 1919-02-25 | Moritz D Schwartz | Metatarsal support. |
| US1298989A (en) * | 1918-11-14 | 1919-04-01 | Reed Foundry & Machine Co | Tractor-plow. |
| US4030910A (en) | 1974-01-22 | 1977-06-21 | The Dow Chemical Company | Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives, herbicidal compositions and methods containing same |
| US4269829A (en) | 1979-06-18 | 1981-05-26 | Rohm And Haas Company | Method and composition for treating helminths containing O,O-dialkyl-N-(substituted phenyl)aminothiocarbonyl phosphoramidates |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
| US6258822B1 (en) | 1997-08-06 | 2001-07-10 | Abbott Laboratories | Urokinase inhibitors |
| PL204619B1 (pl) | 1998-03-19 | 2010-01-29 | Vertex Pharma | Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej |
| WO1999048859A1 (en) | 1998-03-20 | 1999-09-30 | Bristol-Myers Squibb Company | Aryloxyanilides and related compounds |
| TWI282785B (en) | 2000-05-30 | 2007-06-21 | Chugai Pharmaceutical Co Ltd | A compound having thrombopoietin-like activities |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| GB0319126D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| US20070208166A1 (en) | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| WO2007079003A2 (en) * | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Amide inhibitors of leukotriene a4 hydrolase |
| JP2012505920A (ja) * | 2008-10-17 | 2012-03-08 | エグゼリクシス， インコーポレイテッド | スフィンゴシン１リン酸塩受容体拮抗薬 |
| KR20110070919A (ko) | 2008-10-17 | 2011-06-24 | 엑셀리시스, 인코포레이티드 | 스핑고신-１-포스페이트 수용체 길항제 및 항마이크로튜블 제제의 상승적 조합물 |
| GB201011411D0 (en) | 2010-07-06 | 2010-08-18 | St Georges Hosp Medical School | Therapeutic compounds and their use |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| WO2012061390A2 (en) | 2010-11-01 | 2012-05-10 | The Penn State Research Foundation | Therapeutic compositions and methods |
| US20130345231A1 (en) | 2011-03-23 | 2013-12-26 | Indiana University Research And Technology Corporation | Anticancer therapeutic agents |
| CN106029632B (zh) * | 2014-02-28 | 2019-06-21 | 国立大学法人东北大学 | 酰胺衍生物 |
| KR102768838B1 (ko) | 2015-09-17 | 2025-02-14 | 시티 오브 호프 | Pcna 억제제 |
-
2016
- 2016-09-16 KR KR1020187010753A patent/KR102768838B1/ko active Active
- 2016-09-16 KR KR1020257004433A patent/KR20250026875A/ko active Pending
- 2016-09-16 CN CN201680066579.9A patent/CN108348512B/zh active Active
- 2016-09-16 JP JP2018514282A patent/JP6966996B2/ja active Active
- 2016-09-16 CA CA2999080A patent/CA2999080C/en active Active
- 2016-09-16 ES ES16847479T patent/ES3040726T3/es active Active
- 2016-09-16 MX MX2021006326A patent/MX2021006326A/es unknown
- 2016-09-16 US US15/760,959 patent/US10550070B2/en active Active
- 2016-09-16 IL IL282400A patent/IL282400B/en unknown
- 2016-09-16 EP EP16847479.9A patent/EP3349754B9/en active Active
- 2016-09-16 MX MX2018003301A patent/MX382996B/es unknown
- 2016-09-16 CN CN202110922191.7A patent/CN113620833A/zh active Pending
- 2016-09-16 WO PCT/US2016/052310 patent/WO2017049206A1/en not_active Ceased
- 2016-09-16 AU AU2016324158A patent/AU2016324158B2/en active Active
- 2016-09-16 EP EP25181629.4A patent/EP4616910A3/en active Pending
-
2018
- 2018-03-16 IL IL258174A patent/IL258174B/en active IP Right Grant
-
2019
- 2019-12-13 US US16/714,062 patent/US10913706B2/en active Active
-
2020
- 2020-07-16 IL IL276115A patent/IL276115B/en active IP Right Grant
- 2020-11-17 AU AU2020270487A patent/AU2020270487B2/en active Active
- 2020-12-01 US US17/108,739 patent/US11345656B2/en active Active
-
2021
- 2021-10-21 JP JP2021172158A patent/JP7399925B2/ja active Active
-
2022
- 2022-04-27 US US17/730,948 patent/US12054447B2/en active Active
- 2022-06-28 IL IL294381A patent/IL294381B2/en unknown
-
2023
- 2023-03-10 AU AU2023201501A patent/AU2023201501B2/en active Active
- 2023-12-05 JP JP2023205089A patent/JP7690553B2/ja active Active
-
2024
- 2024-06-26 US US18/755,058 patent/US12435030B2/en active Active
-
2025
- 2025-05-28 JP JP2025088605A patent/JP2025128193A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| EP4616910A3 (en) | Pcna inhibitors | |
| MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
| PH12017501999A1 (en) | K-ras modulators | |
| EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| GEAP202014670A (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX2019005833A (es) | Administracion transdermica de agentes grandes. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| SG11201610273VA (en) | Ezh2 inhibitors for treating lymphoma | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| MX390320B (es) | Farmaco de combinacion. |